Core One Labs

Core One Labs

Symbol: OTC:CLABF
  • Outstanding Shares: 15,633,037 (as of 11/30/2021)
  • Float: 13,584,524 (as of 09/01/2021)

www.core1labs.com

Core One Labs is a biotech company focused on bringing psychedelic medicine to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Under the guidance of world-leading microbiologist Executive Chairman Dr. Bob Hancock, Core One is developing new ways for producing psilocybin at a fraction of the price of the current market. Estimated market price is $7,000 to $10,000 USD per gram for synthetic psilocybin used in clinical trials. By using Core One’s biosynthetic expression system, pharma-grade psilocybin can be produced cost effectively for $10s to $100s of dollars.

Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs logo

Recent News

MUST READ OTC MARKETS/SEC POLICY ON STOCK PROMOTION AND INVESTOR PROTECTION
DISCLAIMER

EMC has been paid $240,000 by Core One Labs, Inc. | Please read our full disclaimer

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.